
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics has shown strong commercial execution, particularly with the easing of REMS requirements for its product, FILSPARI, which is expected to enhance prescriber adoption. The solid position of sparsentan as a foundational therapy in IgA nephropathy, along with accelerating sales and progress in the Japanese regulatory pathway, reflects substantial growth potential. The favorable stock market reaction following the cancellation of the Advisory Committee meeting further underscores the positive sentiment surrounding the company's recent developments.
Bears say
The negative outlook on Travere Therapeutics's stock is primarily driven by potential challenges in securing future funding and the risk of failed or inconclusive clinical trials for its pipeline candidate, sparsentan, which targets rare kidney disorders. Increased scrutiny stemming from recent FDA actions, including leadership changes and shifting review practices, has heightened uncertainty and prompted investor trepidation within the biotech sector. Overall sentiment has been mixed regarding regulatory decisions, posing additional risks to the company's development pathway and investor confidence.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares